News articles about InVitae Corp (NASDAQ:NVTA) have trended positive recently, according to AlphaOne. The research group, a subsidiary of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. InVitae Corp earned a media sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave media coverage about the medical research company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s rankings:
- IRHYTHM TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) (4-traders.com)
- Share Activity Lifted for Invitae Corp (NVTA) in Session – Financial News Review (finnewsreview.com)
- Can This Stock Build Some Momentum: Invitae Corp (NVTA) – Bulletin News (orobulletin.com)
- Zacks: Brokerages Expect InVitae Corp (NVTA) Will Announce Quarterly Sales of $13.02 Million (americanbankingnews.com)
- Featured Company News – Invitae Acquires Ommdom; Gets CancerGene Connect Under its Portfolio (finance.yahoo.com)
A number of analysts recently weighed in on NVTA shares. ValuEngine upgraded shares of InVitae Corp from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Benchmark Co. restated a “buy” rating and set a $16.00 target price (up from $11.00) on shares of InVitae Corp in a report on Monday, April 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. InVitae Corp has a consensus rating of “Hold” and a consensus target price of $12.69.
Shares of InVitae Corp (NASDAQ:NVTA) opened at 9.35 on Friday. The company’s 50-day moving average is $9.49 and its 200-day moving average is $9.33. The company’s market capitalization is $395.64 million. InVitae Corp has a one year low of $5.76 and a one year high of $11.88.
InVitae Corp (NASDAQ:NVTA) last issued its quarterly earnings results on Tuesday, May 9th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.04. The business had revenue of $10.34 million for the quarter, compared to analyst estimates of $10.90 million. During the same quarter in the prior year, the firm earned ($0.80) EPS. The firm’s quarterly revenue was up 161.1% compared to the same quarter last year. Equities analysts predict that InVitae Corp will post ($2.37) earnings per share for the current year.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.